

Special Issue

Research on New Strategies for Tumor Therapy Based on Nanostructured Materials

Message from the Guest Editor

Despite being one of the most investigated diseases, cancer is still causing excessive burden that reaches much further than the affected person. Nanomaterial-based therapies, in addition to biological-based approaches, are one of the fastest developing new modalities to fight cancer. These efforts have already resulted in hundreds of new modalities based on unique and sometimes unexpected properties of nanomaterials. Being inorganic, organic, or biomaterial-based; "soft" or "hard"; with a core or hollow; and serving as either carriers of drugs, radioisotopes, or immune system triggers, these materials are proven to be capable of fighting cancers. However, this battle is far from over. Rather, it is just beginning. Relying on an endless pool of unique properties of nanomaterials, new modalities appear every day. In this Special Issue, we would like to shed light on the recent status and offer a glimpse of the future perspective of fighting cancer using the unique properties of nanomaterials.

Guest Editor

Dr. Željko Prijić

Vinča Institute of Nuclear Sciences—National Institute of the Republic of Serbia, University of Belgrade, 11001 Belgrade, Serbia

Deadline for manuscript submissions

closed (20 January 2025)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/183369

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).